000298617 001__ 298617
000298617 005__ 20250210163709.0
000298617 0247_ $$2doi$$a10.1007/s00066-025-02368-1
000298617 0247_ $$2pmid$$apmid:39918562
000298617 0247_ $$2ISSN$$a0179-7158
000298617 0247_ $$2ISSN$$a1439-099X
000298617 037__ $$aDKFZ-2025-00317
000298617 041__ $$aEnglish
000298617 082__ $$a610
000298617 1001_ $$00000-0001-9086-2066$$aFuchs, F.$$b0
000298617 245__ $$aRadio(chemo)therapy in anal cancer: evaluation of sex-specific disparities across AJCC stages.
000298617 260__ $$aHeidelberg$$bSpringer Medizin$$c2025
000298617 3367_ $$2DRIVER$$aarticle
000298617 3367_ $$2DataCite$$aOutput Types/Journal article
000298617 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1739198352_13025
000298617 3367_ $$2BibTeX$$aARTICLE
000298617 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298617 3367_ $$00$$2EndNote$$aJournal Article
000298617 500__ $$aepub
000298617 520__ $$aThis study aimed to investigate sex differences in anal squamous cell carcinomas (ASCC), with a particular focus on the prognostic significance of the American Joint Committee on Cancer (AJCC) 9th edition staging system for oncological outcome.A retrospective analysis was conducted in 188 patients with histologically confirmed ASCC who underwent definitive (chemo)radiotherapy between 2004 and 2020. Patient- and tumor-related data were collected. Tumor stage groups were classified according to the AJCC 9th edition. Overall survival (OS), disease-free survival (DFS), freedom from recurrence (FFR), and colostomy-free survival (CFS) were analyzed using the Kaplan-Meier method for univariate testing and Cox regression models for multivariate analysis. Differences between sexes were assessed.The cohort included 134 females and 54 males, with a median follow-up of 83 months. Females exhibited significantly better OS (p = 0.01), DFS (p = 0.01), and CFS (p = 0.03). For male patients, there was a clear trend towards better OS (p = 0.08), DFS (p = 0.10), and FFR (p = 0.09) in earlier tumors as well as significantly better CFS (p = 0.04). In contrast, in the female subgroup, there were no significant differences in OS (p = 0.64), DFS (p = 0.52), and CFS (p = 0.25) with respect to tumor stage. In multivariate analysis, male sex, older age, and advanced tumor stages were significant risk factors for poorer OS, DFS, and CFS.This study highlights significant sex differences in ASCC prognoses, with females showing better survival outcomes. The prognostic value of the AJCC 9th edition staging system differs between sexes; thus, we support the inclusion of sex as a prognostic factor in staging systems.
000298617 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000298617 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298617 650_7 $$2Other$$aAJCC staging system
000298617 650_7 $$2Other$$aAnal carcinoma
000298617 650_7 $$2Other$$aChemoradiotherapy
000298617 650_7 $$2Other$$aGender medicine
000298617 650_7 $$2Other$$aSex disparities
000298617 7001_ $$aRogowski, P.$$b1
000298617 7001_ $$aRottler, M.$$b2
000298617 7001_ $$aShouman, M. A.$$b3
000298617 7001_ $$0P:(DE-He78)576a6e2597f0f9f0143afc1cea3e3048$$aHeinrich, Katja$$b4
000298617 7001_ $$0P:(DE-HGF)0$$aKühn, F.$$b5
000298617 7001_ $$0P:(DE-HGF)0$$aBelka, C.$$b6
000298617 7001_ $$0P:(DE-HGF)0$$aUnger, K.$$b7
000298617 7001_ $$0P:(DE-He78)3173c18bbe3efc61c82d620d77dfd391$$aWalter, Florin$$b8$$udkfz
000298617 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-025-02368-1$$pnn$$tStrahlentherapie und Onkologie$$vnn$$x0179-7158$$y2025
000298617 909CO $$ooai:inrepo02.dkfz.de:298617$$pVDB
000298617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)576a6e2597f0f9f0143afc1cea3e3048$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000298617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000298617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000298617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000298617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3173c18bbe3efc61c82d620d77dfd391$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000298617 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000298617 9141_ $$y2025
000298617 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000298617 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000298617 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2022$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000298617 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000298617 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000298617 980__ $$ajournal
000298617 980__ $$aVDB
000298617 980__ $$aI:(DE-He78)MU01-20160331
000298617 980__ $$aUNRESTRICTED